Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 25034862

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2014 Sep 20
First author
Robert C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2014 Sep 20;384(9948):1078-9. doi: 10.1016/S0140-6736(14)61140-5.
    note
    Source null
    related pmid
    25034863
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2014 Sep;11(9):502. doi: 10.1038/nrclinonc.2014.132.
    note
    Source null
    related pmid
    25091612
    relationship
    Comment in

Authors and identifiers

  1. name
    Robert C
    type
    Author
  2. name
    Ribas A
    type
    Author
  3. name
    Wolchok JD
    type
    Author
  4. name
    Hodi FS
    type
    Author
  5. name
    Hamid O
    type
    Author
  6. name
    Kefford R
    type
    Author
  7. name
    Weber JS
    type
    Author
  8. name
    Joshua AM
    type
    Author
  9. name
    Hwu WJ
    type
    Author
  10. name
    Gangadhar TC
    type
    Author
  11. name
    Patnaik A
    type
    Author
  12. name
    Dronca R
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Robert C
    type
    Author
  2. name
    Ribas A
    type
    Author
  3. name
    Wolchok JD
    type
    Author
  4. name
    Hodi FS
    type
    Author
  5. name
    Hamid O
    type
    Author
  6. name
    Kefford R
    type
    Author
  7. name
    Weber JS
    type
    Author
  8. name
    Joshua AM
    type
    Author
  9. name
    Hwu WJ
    type
    Author
  10. name
    Gangadhar TC
    type
    Author
  11. name
    Patnaik A
    type
    Author
  12. name
    Dronca R
    type
    Author
bibliography ids
  1. nci-bib-ad5f1d21169f82047b1c3e2a
book metadata
content sha256
76e164b1e623b2d8ae9fc894932a9ba98c071837c227a77d71c558fbb64a22e9
document type
citation
dois
  1. 10.1016/S0140-6736(14)60958-2
electronic publication date
display
2014 Jul 15
precision
day
year
2014
evidence scope
bibliographic_metadata_only
id
pubmed:25034862
immutable id
pubmed:25034862@76e164b1e623b2d8ae9fc894932a9ba98c071837c227a77d71c558fbb64a22e9
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
9948
name
Lancet (London, England)
nlm unique id
2985213R
pages
1109-17
volume
384
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2014 Sep 20;384(9948):1078-9. doi: 10.1016/S0140-6736(14)61140-5.
    note
    Source null
    related pmid
    25034863
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2014 Sep;11(9):502. doi: 10.1038/nrclinonc.2014.132.
    note
    Source null
    related pmid
    25091612
    relationship
    Comment in
outcomes validated
false
pmid
25034862
provenance
batch id
69903be8ceab8801c81a
provider
NCBI PubMed ESummary
record sha256
4cea503ff1577754b4fc22c6cf333b58d199d8113fda8f4e920fb0858f635bb5
response sha256
1e367491c3c459a93f45b3db99ca1f9293ed2287c48bdf758bb088ffcd7c96eb
retrieved at
2026-09-09T23:47:05.208886+00:00
publication date
display
2014 Sep 20
precision
day
year
2014
publication types
  1. Clinical Trial, Phase I
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/25034862/
title
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Preserved source evidence · Not medical advice